Navigating risk in the OTC space with enhanced market data
How can access to more reliable market data help participants in the OTC derivatives market navigate liquidity risks and identify market opportunities in an evolving sector?
Our exclusive survey of perspectives from leading participants in the OTC market has revealed a sector well-placed to lay the foundations for more effective operations in 2024 and beyond. There are high levels of confidence among market participants that they have the capabilities needed to carry the market forwards, and a general openness to embracing innovation. Given this, the stage is certainly set for smoother operations at an opportune moment for OTC derivatives, which are seen as a promising hedge against volatility.
Chapter three of our state-of-the-market report explores how access to reliable, in-depth data can be used to strike the right balance between risks and opportunities in an evolving market.
Navigating liquidity challenges
An increase in regulatory oversight and the establishment of central counterparties (CCPs) has put the OTC space on a more stable footing than previous years, which is an important milestone for establishing confidence in the sector’s growth potential – it is currently projected to reach $25.81 trillion by 2032. However, while growing regulation has helped lift market confidence, respondents are concerned by a subsequent decrease in liquidity in the market, driven in no small part by historically high interest rates.
Risks posed by this growth in liquidity challenges include rising price volatility, a lack of CCPs willing to engage in large trades, and greater difficulty entering and exiting market positions. Given the challenges present in the market, there is a greater need for more data to power the algorithms and models that can help participants more effectively manage risk and identify opportunities.
Many buy-side respondents worry that they are over-reliant on the sell-side for their information and would benefit from open and accountable third party data providers to get a better (and more objective) read on the market.
Supporting the AI transition
As the OTC markets evolve , there will be a greater need for access to data in order to support the market’s transition to AI-powered infrastructure. It’s an encouraging outcome of our survey that market participants broadly support this move to leverage AI and machine learning in order to improve processes and unlock profitability.
However, despite overall confidence within the market that there is enough data available, there are concerns among some the buy-side that there is not currently enough data to support this transition without incurring additional risk. When the focus shifts to areas of APAC such as Hong Kong, these concerns grow stronger, with significantly less confidence in the levels of data needed.
While the markets seem generally aligned on the potential for harnessing AI in order to deliver enhanced execution, it is important the buy-side is supported to overcome any barriers to fully realizing the benefits. With the OTC space at an inflection point for growth and change, there is a need for all parties to embrace a mindset of adaptability and to gain a fuller understanding of the risks – and opportunities – present in the market. Read the report for more insights. Learn about managing risk in the OTC market
Disclaimer
© 2025 ICAP Information Services Limited (“IISL”). This communication is provided by ICAP Information Services Limited or a member of its group (“Parameta”) and all information contained in or attached hereto (the “Information”) is for information purposes only and is confidential. Access to the Information by anyone other than the intended recipient is unauthorised without Parameta’s prior written approval. The Information may not be not used or disclosed for any purpose without Parameta’s prior written approval, including without limitation, storing, copying, distributing, licensing, selling or displaying the Information, using the Information in an application or to create derived data of any kind, co-mingling the Information with any other data or using the data for any unlawful purpose of for any purpose that would cause it to become a benchmark under any law, regulation or guidance. The Information is not, and should not be construed as, a live price, an offer, bid, recommendation or solicitation in relation to any financial instrument or investment or to participate in any particular trading strategy or constituting financial or investment advice or a financial promotion. The Information does not constitute a public offer under any applicable legislation or an offer to sell or a solicitation of an offer to buy any securities. The Information is not to be relied upon for any purpose whatsoever and is provided “as is” without warranty of any kind, either expressly or by implication, including without limitation as to completeness, timeliness, accuracy, continuity, merchantability or fitness for any particular purpose. All representations and warranties are expressly disclaimed, to the fullest extent possible under applicable law. In no circumstances will Parameta be liable for any indirect or direct loss, or consequential loss or damages including without limitation, loss of business or profits arising from the use of, any inability to use, or any inaccuracy in the Information. Parameta may suspend, withdraw or modify or change the terms of the provision of the Information at any time in its sole discretion, without notice. All rights, including without limitation intellectual property rights, in and to the Information are, and shall remain, the property of IISL or its licensors. Use of, access to or delivery of Parameta’s products and/or services requires a prior written licence from Parameta or its relevant affiliates. The terms of this disclaimer are governed by the laws of England and Wales.
